Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balugrastim Dose Finding Study in Pediatric Solid Tumors
NCT01940601Phase 2Withdrawn
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2014
- Primary completion
- Nov 2015
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of balugrastim in chemotherapy-induced neutropenia (CIN), sponsored by Teva Pharmaceutical Industries Ltd.. Planned start Sep 2014; status: withdrawn.
02
Drugs
balugrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT01940601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940601.